Lurbinectedin is a medication that is used for the treatment of certain types of cancer. While it has shown promise in clinical trials, it is important to consider the potential risks it may pose to fetal development if used during pregnancy.

According to the drug label provided by the U.S. Food and Drug Administration (FDA), lurbinectedin is classified as a Pregnancy Category D drug. This means that there is evidence of fetal risk based on human data, but the potential benefits of the drug may outweigh the risks in certain situations. The label specifically advises against the use of lurbinectedin during pregnancy unless the potential benefits to the mother outweigh the potential risks to the fetus [2].

The National Cancer Institute also mentions that lurbinectedin may cause harm to the developing fetus and recommends that women of childbearing potential use effective contraception during treatment with this medication [3].

It is worth noting that the available information on the specific risks of lurbinectedin on fetal development is limited. The drug patent information does not provide specific details about the potential risks to fetal development [1]. However, it is important to consider that many chemotherapy drugs, including lurbinectedin, can potentially cause harm to the developing fetus due to their mechanisms of action.

It is crucial for pregnant women or women planning to become pregnant to discuss the potential risks and benefits of lurbinectedin treatment with their healthcare provider. They can provide personalized advice based on the individual's medical history and the specific cancer being treated.

In conclusion, lurbinectedin is classified as a Pregnancy Category D drug, indicating potential risks to fetal development. The drug label advises against its use during pregnancy unless the potential benefits outweigh the risks. Women of childbearing potential should use effective contraception during treatment with lurbinectedin. However, specific information about the risks to fetal development is limited, and it is important to consult with a healthcare provider for personalized advice [2][3].

Sources:
[1] Drug Patent Watch. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] U.S. Food and Drug Administration. (2020). Lurbinectedin Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] National Cancer Institute. (n.d.). Lurbinectedin in Treating Patients with Metastatic Solid Tumors or Advanced Solid Tumors That Cannot Be Removed by Surgery. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-00578